Balyasny Asset Management
PHAT icon

Balyasny Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Balyasny Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-95,301
Closed -$1.06M – 3390
2026
Q1 		$1.06M Sell
95,301
-111,784
-54% -$1.41M ﹤0.01% 2054
2025
Q4 		$3.44M Sell
207,085
-88,076
-30% -$1.26M ﹤0.01% 1591
2025
Q3 		$3.47M Buy
295,161
+281,979
+2,139% +$2.91M ﹤0.01% 1550
2025
Q2 		$126K Sell
13,182
-32,649
-71% -$181K ﹤0.01% 2666
2025
Q1 		$287K Buy
+45,831
New +$278K ﹤0.01% 2466
2024
Q4 		– Sell
-65,659
Closed -$1.19M – 3150
2024
Q3 		$1.19M Buy
65,659
+50,653
+338% +$708K ﹤0.01% 1894
2024
Q2 		$155K Buy
+15,006
New +$155K ﹤0.01% 2374
2022
Q4 		– Sell
-18,532
Closed -$205K – 3128
2022
Q3 		$205K Buy
+18,532
New +$177K ﹤0.01% 2305

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Balyasny Asset Management's PHAT Position: Q2 2026 in Review

Balyasny Asset Management sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 95,301 shares — an estimated $1.06M sold.

Balyasny Asset Management first reported a position in PHAT in Q3 2022 and held it in 8 quarters. The position peaked at $3.47M in Q3 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Balyasny Asset Management reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 95,301 Phathom Pharmaceuticals shares in Q2 2026, an estimated $1.06M.
  • Balyasny Asset Management first reported a position in Phathom Pharmaceuticals in Q3 2022 and held it in 8 quarters.
  • Balyasny Asset Management's Phathom Pharmaceuticals position peaked at $3.47M in Q3 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.